Fortitude Family Office’s Sutro Biopharma STRO Stock Holding History

Fortitude Family Office’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.86K	Hold	56	–	–	﹤0.01%	1505
2026 Q1	$1.4K	Hold	56	–	–	﹤0.01%	1410
2025 Q4	$648	Buy	+56	New	+$531	﹤0.01%	1618

Other funds holding STRO

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

OCWP

Owl Creek Wealth Partners Denver, Colorado $342M AUM

PWA

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

Fortitude Family Office's STRO Position: Q2 2026 in Review

Fortitude Family Office held its Sutro Biopharma (STRO) position steady in Q2 2026 at 56 shares worth $1.86K. The position accounts for ﹤0.01% of the portfolio, ranked #1505.

Fortitude Family Office first reported a position in STRO in Q4 2025 and has held it in 3 quarters since. 5 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

Fortitude Family Office held 56 shares of Sutro Biopharma worth $1.86K as of Q2 2026.
Fortitude Family Office left its Sutro Biopharma share count unchanged in Q2 2026.
Sutro Biopharma made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1505 holding.
Fortitude Family Office first reported a position in Sutro Biopharma in Q4 2025 and has held it in 3 quarters since.
5 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.